王永辉
药物化学, 研究员, 博士生导师

姓      名

王永辉

性      别

 男

职      称

研究员

学      历

 博士

电      话

021-51980118

传      真

 

电子邮件

yonghuiwang@fudan.edu.cn

个人主页

 

通讯地址

上海市浦东新区张衡路826号

教育经历 
1997.08 – 2001.08 美国哈佛大学化学和化学生物学系,有机化学专业,博士后
1993.08 – 1997.08 美国弗吉尼亚理工大学化学系,有机化学专业,博士
1983.09 – 1985.12 东北大学化学系,分析化学专业,硕士
1979.09 – 1983.07 河南师范大学化学系,化学专业,学士
 
工作经历 
2014.01 – 现在        复旦大学药学院,特聘研究员、博士生导师;上海药物创制产业化开发中心,化学部主任;上海“千人计划”专家
2008.10 – 2013.12  葛兰素史克制药公司(上海)研发中心,副总监
2001.08 – 2008.10  葛兰素史克制药公司(美国费城)研发中心,研究员
1985.12 – 1993.08  西安建筑科技大学环境工程学院,助教、讲师

 

研究方向
1. 炎症免疫小分子药物发现
2. 靶向抗癌小分子药物发现
3. 基于表型筛选的小分子药物发现

代表性论著

1. Discovery of biaryl amides as potent, orally bioavailable and CNS penetrant ROR?t inhibitors. ACS Med. Chem. Lett.,2015,6, 787-792 (1st and corresponding author).
2. Discovery of N-(4-aryl-5-aryloxy-thiazol-2-yl)-amides as potent ROR?t inverse agonists.Bioorg. Med. Chem2015, 23, 5293-5302(1st and corresponding author).
3. Small molecule ROR?t antagonists inhibit T helper 17 cell transcriptional network by divergent mechanisms. Immunity2014, 40, 477-489 (4th author)
4. Discovery of novel N-(5-(arylcarbonyl)thiazol-2-yl)amides andN-(5-(arylcarbonyl)thiophen-2-yl)amides as potent ROR?t inhibitors. Bioorg. Med. Chem.2014, 22, 692-702. (1st and corresponding author)
5. Discovery of tertiary amine and indolederivatives as potent ROR?tinverse agonists. ACS Med. Chem. Lett.2014, 5, 65-68. (corresponding author)

 

代表性专利
1. Preparation of N-substituted 2-[4-(ethylsulfonyl)phenyl]acetamides as retinoid-related orphan receptor gamma modulators. WO2013029338A1, Published on 03/07/2013
2. Preparation of thiazole derivatives as modulators of retinoid-related orphan receptor gamma. WO2012027965A1; Published on 03/08/2012
3. N-Glycinylpyridinedicarboxamide derivatives as HIF prolyl hydroxylase inhibitors and their preparation, pharmaceutical compositions and use in the treatment of anemia. WO2009158315A1, Published on 12/30/2009; US20110098324A1/ EP2306828A1/ JP2011525924T, applied on 2011
4. Preparation of aminosulfonyl-N-thiadiazolylbenzamide for use as IL-8 receptor Antagonists. WO2008070707A1 , Published on 06/12/2008; US8044075B2, granted on 10/25/2011
5. Preparation of N-[(piperazinylmethyl)biphenyl]benzamide derivatives as M3 muscarinic acetylcholine receptor antagonists. WO2006055553A2, Published on 05/26/2006; US7932247B2, granted on 04/26/2011

 

打印 返回